8. Complete and abbreviated physical examinations : A neurologic examination must be conducted at Screening to look for potential signs of underlying autoimmune disorders. In addition, all abbreviated physical examinations conducted during Cycle 1 must include a neurologic examination. 9. Assessment of the Skin and Subcutaneous Tissue Thickness: Assessment of the skin and subcutaneous tissue thickness at the eligible administration sites will be performed at screening as described in the TDS-IM Instructions for Use. The assessment procedure does not need to be repeated during the course of the study unless the participant experiences a greater than 10% change in body mass relative to screening. 10. Vital signs: Includes temperature, pulse, and blood pressure (BP) to be recorded in the seated position after approximately 5 minutes of rest. Vitals signs, including temperature, pulse, and BP to be recorded 1-hour post-study drug administration during each cycle on Days 1, 29, 57, and 85.C CI PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 31Protocol Activity Screen 1 (28 days)Treat ment Period Post Treat ment Cycle 1 Cycle 2 End of Treat ment 32Follow -Up (Months after EOT visit)Survival Follow -up34 Study Day Day 1Day 8Day 15Day 22Day 29Day 43Day 57Day 71Day 85Day 113Month 133Month 2 Month 4 Month 6 Post 6 -Month Follow -up Cycle Day Day 1Day 29Day 57Day 85Day 9928 to 35 daysEvery 3 Months Visit Window (Days) *1±2 ±2 ±2 ±4 ±2 ±4 ±2 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±10 11. Performance status : Use Eastern Cooperative Oncology Group (ECOG) – see Appendix 2.